• Publications
  • Influence
Primary central nervous system post‐transplantation lymphoproliferative disorder
Primary central nervous system (CNS) post‐transplantation lymphoproliferative disorder (PCNS‐PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to defineExpand
  • 137
  • 10
Clinical implications of status epilepticus in patients with neoplasms.
OBJECTIVES To elucidate factors that contribute to the development of status epilepticus (SE) and determine prognostic factors and the impact on 30-day survival. DESIGN Retrospective review ofExpand
  • 54
  • 5
Low-grade gliomas: an update on pathology and therapy
Low-grade gliomas (LGG) are not benign neoplasms. Patients with LGG eventually die as a consequence of this disease. Although the survival of patients with LGG is better than that of patients withExpand
  • 121
  • 4
Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis, and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ System is a novelExpand
  • 70
  • 4
Stereotactic Radiosurgery With or Without Whole Brain Radiotherapy for Patients With a Single Radioresistant Brain Metastasis
Purpose:To examine the outcomes of patients with a single brain metastasis from radioresistant histologies (renal cell carcinoma and melanoma) treated with stereotactic radiosurgery (SRS) with orExpand
  • 26
  • 4
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
PURPOSE Despite aggressive therapies, median survival for malignant gliomas is less than 15 months. Patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) fare worse, presumablyExpand
  • 98
  • 3
Brain Tumor Imaging and Cancer Management: The Neuro-Oncologists Perspective
Brain tumors remain a significant cause of morbidity and mortality and are often refractory to treatment. Neuroimaging, in particular magnetic resonance imaging (MRI) and associated techniques, hasExpand
  • 16
  • 2
Novel therapies for malignant gliomas.
The impact of cytotoxic therapies on the outcome of glioblastoma has been modest thus far. Yet it is clear that subsets of high-grade gliomas exist that are sensitive to treatment. Patients deemedExpand
  • 17
  • 2
Stereotactic radiosurgery alone for patients with 1–4 radioresistant brain metastases
Brain metastases from radioresistant histologies are perceived to be less responsive to WBRT compared to other histologies, and stereotactic radiosurgery (SRS) may provide better local control. TheExpand
  • 21
  • 1
Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib
Optimal treatment of metastases to the central nervous system (CNS) in patients with malignant melanoma remains a clinical challenge. In particular, for patients with BRAF-mutant melanoma and CNSExpand
  • 26
  • 1